Evidence from a small randomized trial that included biopsy-proven NAFLD patients demonstrated a decrease in the hepatic steatosis (assessed by MRS) as well as improvement in insulin sensitivity (IS) [68]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.